Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4Terminated 3Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Neoplasms 282Carcinoma, Non-Small-Cell Lung 253Leukemia, Myeloid, Acute 190Breast Neoplasms 153Melanoma 151Neoplasm Metastasis 148Multiple Myeloma 127Recurrence 123Colorectal Neoplasms 119Lymphoma, Non-Hodgkin 114Lymphoma 113Leukemia, Lymphocytic, Chronic, B-Cell 108Pancreatic Neoplasms 99Ovarian Neoplasms 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Leukemia 86Prostatic Neoplasms 83Lung Neoplasms 82Lymphoma, Large B-Cell, Diffuse 77Squamous Cell Carcinoma of Head and Neck 76Glioblastoma 73Carcinoma, Renal Cell 72Myelodysplastic Syndromes 68Lymphoma, Follicular 65Brain Neoplasms 60Lymphoma, Mantle-Cell 55Sarcoma 53Stomach Neoplasms 52Head and Neck Neoplasms 52Triple Negative Breast Neoplasms 51

Interventions

Dexamethasone 2Calcium Dobesilate 2venetoclax 1pomalidomide 1Surveys and Questionnaires 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Amyloidosis × Clear all
NCT03000660 2020-08-21

Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Tufts Medical Center

Phase 1 Terminated
3 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT02603172 2019-09-23

A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis

GlaxoSmithKline

Phase 1 Terminated
23 enrolled 25 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01807286 2016-05-13

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Terminated
3 enrolled
Plasma cell

Amyloidosis, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡